Soft Tissue Sarcoma
Conditions
Brief summary
Primary Objective: 1\. To evaluate the efficacy of glufosfamide in subjects with advanced soft tissue sarcoma as measured by objective response rate Secondary Objectives: 1. To evaluate the efficacy of glufosfamide in subjects with advanced soft tissue sarcoma as measured by duration of response, progression-free survival and overall survival 2. To evaluate the safety of glufosfamide in subjects with advanced soft tissue sarcoma Exploratory Objectives: 1. To evaluate the biological effect of glufosfamide on the metabolic profile in subjects with advanced soft tissue sarcomas, as determined by FDG-PET 2. To correlate efficacy endpoints with expression of tumor-associated glucose transporter proteins
Interventions
DRUGGlufosfamide
5000 mg/m2 of glufosfamide on Day 1 of each three-week cycle for up to 6 cycles.
Sponsors
Threshold Pharmaceuticals
Eleison Pharmaceuticals LLC.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* At least 18 years of age * Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee * Pathologically confirmed diagnosis of soft tissue sarcoma * Locally advanced unresectable or metastatic disease with no standard curative therapy available that has progressed since the most recent therapy * Measurable disease by RECIST criteria with at least one target lesion * 1 or 2 prior chemotherapy/systemic therapy regimens for advanced disease * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2 * A minimum of 3 weeks between prior chemotherapy, radiation therapy, immunotherapy, or other anti-tumor therapy and study entry * Recovered from reversible toxicities of prior therapy * Hemoglobin ≥ 9.0 g/dL, neutrophils ≥ 1,500/µL, platelets ≥ 100,000/µL * Total bilirubin ≤ 1.5-fold ULN, AST/ALT ≤ 2.5-fold ULN (≤ 5-fold if liver metastases) * Normal creatinine clearance (≥85 mL/min for men and ≥75 mL/min for women; calculated by Cockcroft-Gault formula * All women of childbearing potential must have a negative serum pregnancy test and all subjects must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) from entry into the study through 6 months after the last dose
Exclusion criteria
* Soft tissue sarcoma of the following subtypes: gastrointestinal stromal tumor (GIST), alveolar soft parts sarcoma, hemangiopericytoma and Kaposi's sarcoma * Most recent relapse occurring during treatment with ifosfamide within 4 weeks of last dose * Symptomatic brain or leptomeningeal metastases * Active clinically significant infection requiring antibiotics * Recent (one year) history or symptoms of cardiovascular disease (NYHA Class 2, 3, or 4), particularly coronary artery disease, arrhythmias or conduction defects with risk of cardiovascular instability, uncontrolled hypertension, clinically significant pericardial effusion, cerebrovascular accident or congestive heart failure * Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years * Major surgery within 3 weeks of the start of study treatment, without complete recovery * Females who are pregnant or breast-feeding * Participation in an investigational drug or device study within 21 days of study entry * Concomitant disease or condition that could interfere with the conduct of the study, or that in the opinion of the investigator would pose an unacceptable risk to the subject in this study * Unwillingness or inability to comply with the study protocol for any other reason
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | Tumor assessments were performed at baseline and every 6 weeks until disease progression was documented. | The event rate was the response rate (complete and partial response) based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.0). The associated 95% exact binomial confidence intervals were calculated. |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free Survival | All subjects were followed regularly until glufosfamide discontinuation, tumor progression or additional antitumor therapy was started and then were followed for survival at 3 month intervals for the first year and once every year thereafter until death. |
| Overall Survival | All subjects were followed regularly until glufosfamide discontinuation, tumor progression or additional antitumor therapy was started and then were followed for survival at 3 month intervals for the first year and once every year thereafter until death. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Glufosfamide Glufosfamide
Glufosfamide: 5000 mg/m2 of glufosfamide on Day 1 of each three-week cycle for up to 6 cycles. | 22 |
| Total | 22 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 6 |
| Overall Study | Progressive disease | 9 |
| Overall Study | Withdrawal by Subject | 3 |
Baseline characteristics
| Characteristic | Glufosfamide |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 4 Participants |
| Age, Categorical Between 18 and 65 years | 18 Participants |
| Age, Continuous | 53.5 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 19 Participants |
| Sex: Female, Male Female | 11 Participants |
| Sex: Female, Male Male | 11 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 22 / 22 |
| serious Total, serious adverse events | 7 / 22 |
Outcome results
Primary
Objective Response Rate
The event rate was the response rate (complete and partial response) based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.0). The associated 95% exact binomial confidence intervals were calculated.
Time frame: Tumor assessments were performed at baseline and every 6 weeks until disease progression was documented.
Population: Patients receiving glufosfamide with a post treatment imaging assessment
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Glufosfamide | Objective Response Rate | Partial response | 1 participants |
| Glufosfamide | Objective Response Rate | Stable disease | 7 participants |
| Glufosfamide | Objective Response Rate | Progressive disease | 11 participants |
Secondary
Overall Survival
Time frame: All subjects were followed regularly until glufosfamide discontinuation, tumor progression or additional antitumor therapy was started and then were followed for survival at 3 month intervals for the first year and once every year thereafter until death.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Glufosfamide | Overall Survival | 10.5 months |
Secondary
Progression-free Survival
Time frame: All subjects were followed regularly until glufosfamide discontinuation, tumor progression or additional antitumor therapy was started and then were followed for survival at 3 month intervals for the first year and once every year thereafter until death.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Glufosfamide | Progression-free Survival | 1.3 months |